Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam.

Maharaj AR, Barrett JS, Edginton AN.

AAPS J. 2013 Apr;15(2):455-64. doi: 10.1208/s12248-013-9451-0. Epub 2013 Jan 24.

2.
3.

Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.

Kersting G, Willmann S, Würthwein G, Lippert J, Boos J, Hempel G.

Cancer Chemother Pharmacol. 2012 Feb;69(2):397-405. doi: 10.1007/s00280-011-1706-9. Epub 2011 Jul 26.

PMID:
21789689
4.

Physiologically based pharmacokinetic (PBPK) modeling in children.

Barrett JS, Della Casa Alberighi O, Läer S, Meibohm B.

Clin Pharmacol Ther. 2012 Jul;92(1):40-9. doi: 10.1038/clpt.2012.64. Epub 2012 Jun 6. Review.

PMID:
22669290
5.

Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients.

Swart EL, Zuideveld KP, de Jongh J, Danhof M, Thijs LG, Strack van Schijndel RM.

Br J Clin Pharmacol. 2004 Feb;57(2):135-45.

6.

Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.

Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM.

Clin Ther. 2011 Jul;33(7):946-64. doi: 10.1016/j.clinthera.2011.06.002. Epub 2011 Jul 7.

PMID:
21741088
7.

Population Pharmacokinetics and Exploratory Pharmacodynamics of Lorazepam in Pediatric Status Epilepticus.

Gonzalez D, Chamberlain JM, Guptill JT, Cohen-Wolkowiez M, Harper B, Zhao J, Capparelli EV; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee.

Clin Pharmacokinet. 2017 Aug;56(8):941-951. doi: 10.1007/s40262-016-0486-0.

PMID:
27943220
9.

Predictive performance of a physiologically based pharmacokinetic model of busulfan in children.

Diestelhorst C, Boos J, McCune JS, Russell J, Kangarloo SB, Hempel G.

Pediatr Hematol Oncol. 2014 Nov;31(8):731-42. doi: 10.3109/08880018.2014.927945. Epub 2014 Jul 9.

PMID:
25007236
10.

Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used?

Salem F, Ogungbenro K, Vajjah P, Johnson TN, Aarons L, Rostami-Hodjegan A.

J Clin Pharmacol. 2014 Mar;54(3):311-7. doi: 10.1002/jcph.206. Epub 2013 Nov 19.

PMID:
24122884
11.

Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.

Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U.

Clin Pharmacokinet. 2016 Dec;55(12):1573-1589.

13.

Integration of modelling and simulation into the development of intravenous busulfan in paediatrics: an industrial experience.

Nguyen L.

Fundam Clin Pharmacol. 2008 Dec;22(6):599-604. doi: 10.1111/j.1472-8206.2008.00651.x.

PMID:
19049661
14.

Development and evaluation of a generic physiologically based pharmacokinetic model for children.

Edginton AN, Schmitt W, Willmann S.

Clin Pharmacokinet. 2006;45(10):1013-34.

PMID:
16984214
15.

Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene.

Nong A, McCarver DG, Hines RN, Krishnan K.

Toxicol Appl Pharmacol. 2006 Jul 1;214(1):78-87. Epub 2006 Feb 7.

PMID:
16464483
16.

Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine.

Crom WR, Relling MV, Christensen ML, Rivera GK, Evans WE.

Clin Pharmacol Ther. 1991 Aug;50(2):132-40.

PMID:
1868674
17.

Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.

Mehrotra N, Bhattaram A, Earp JC, Florian J, Krudys K, Lee JE, Lee JY, Liu J, Mulugeta Y, Yu J, Zhao P, Sinha V.

Drug Metab Dispos. 2016 Jul;44(7):924-33. doi: 10.1124/dmd.116.069559. Epub 2016 Apr 14. Review.

18.

Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.

Kontny NE, Würthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jörger M, Schellens JH, Hempel G.

Cancer Chemother Pharmacol. 2013 Mar;71(3):749-63. doi: 10.1007/s00280-013-2069-1. Epub 2013 Jan 13.

PMID:
23314734
19.

A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model.

Barr J, Zomorodi K, Bertaccini EJ, Shafer SL, Geller E.

Anesthesiology. 2001 Aug;95(2):286-98.

PMID:
11506097
20.

Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.

Thai HT, Mazuir F, Cartot-Cotton S, Veyrat-Follet C.

Br J Clin Pharmacol. 2015 Sep;80(3):534-47. doi: 10.1111/bcp.12702. Epub 2015 Aug 14.

Supplemental Content

Support Center